drugset
drugset / Trial / NCT00984646

Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)

NCT00984646 ↗

Phase 2 Completed 175 enrolled Renovo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to investigate the scar-reducing properties of eight doses of intradermal Prevascar (IL-10).

Timeline

Start
2005-04
Primary completion
2006-11
Completion
2006-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ILODECAKIN Protein / enzyme biologic 5 ng Other
Subject ILODECAKIN Protein / enzyme biologic 25 ng Other
Subject ILODECAKIN Protein / enzyme biologic 50 ng Other
Subject ILODECAKIN Protein / enzyme biologic 125 ng Other
Subject ILODECAKIN Protein / enzyme biologic 250 ng Other
Subject ILODECAKIN Protein / enzyme biologic 500 ng Other
Subject ILODECAKIN Protein / enzyme biologic 1000 ng Other
Subject ILODECAKIN Protein / enzyme biologic 2000 ng Other

Indications

No indication recorded.